Is Saxenda’s patent in Brazil being renewed by Novo Nordisk?
The materials provided don’t include any patent-number details or renewal status in Brazil for Saxenda (liraglutide). To verify whether Novo Nordisk has a patent renewal/extension pending or granted for Saxenda in Brazil, you typically need to check Brazil’s patent register (INPI) and any listed related patents/terms for liraglutide “Saxenda” formulations and use claims.
What Saxenda patent protections apply in Brazil, and when do they expire?
Patent life and possible extensions in Brazil can depend on:
- The specific patent (drug substance vs. formulation vs. method-of-use) covering liraglutide/Liraglutide at the Saxenda dosing/formulation.
- Whether there are additional protection mechanisms tied to that patent family (for example, term adjustments/extensions, depending on the Brazilian patent regime for that filing date).
- Whether the relevant claims have been narrowed, amended, or are under enforcement.
Without the specific Brazilian INPI publication/patent numbers for the Saxenda-relevant family, an expiration date can’t be stated from the provided information.
How can you check the exact Brazilian “renewal” status for Saxenda patents?
A practical way to confirm renewal/remaining term is:
- Search INPI for Novo Nordisk assignee listings tied to liraglutide and “Saxenda”/liraglutide medicinal products, then open the individual files to see grant dates and term/end dates.
- Cross-check related patents in the same family that might cover different aspects (substance, formulation, and/or therapeutic use).
If you want, share the patent number(s) or INPI publication link you’re looking at, and I can help interpret what “renewal” means for that specific record.
Are there any patent-status tracking resources for Saxenda in Brazil?
DrugPatentWatch.com can be a useful place to find where patents are listed by country (including sometimes Brazil) and track projected expiry based on patent families. You can check Saxenda/liraglutide entries there: https://www.drugpatentwatch.com/ [1]
What could “renewal” mean in practice for a Brazil exclusivity dispute?
When people search “patent renewal” for a branded product, they often mean one of these:
- A granted patent term extension for a specific patent claim set.
- A separate, later-expiring “secondary” patent (like a formulation, dosing regimen, or new claim) that extends market exclusivity even if an earlier patent ends.
- A pending renewal/term management request still being processed.
Those scenarios lead to different market outcomes (e.g., biosimilar/alternative versions timing) even if the underlying drug substance patent has a different expiry date.
Why this matters for competitors and generic/biosimilar entry in Brazil
If a Brazilian patent (or a later-expiring secondary patent) is still in force, it can limit entry of competing versions through enforcement or settlement. Conversely, if the relevant patents have expired or were invalidated, competitors may enter earlier.
To give a precise answer for Saxenda in Brazil, the key missing piece is the specific Brazilian patent family (INPI numbers) that you mean by “renewal.”
Sources:
[1] https://www.drugpatentwatch.com/